Dapagliflozin (Amorphous) API Manufacturer and Supplier

API Solutions

Dr. Reddy's API business supplies high-quality, affordable APIs to leading generic formulations manufacturers and is the preferred API partner for pharma companies in more than 100 countries.

R&D

Dr. Reddy’s supplies generic APIs to 80+ countries, excelling in R\&D across niche molecules and key therapies, with capabilities from lab to production in contained/non-contained APIs and advanced chemical processes.

White Paper

Dr. Reddy’s offers insightful whitepapers sharing expertise on APIs, formulations, regulatory trends, and industry innovations, helping global pharma partners gain knowledge, solve challenges, and drive faster, compliant product development.

About Dapagliflozin (Amorphous) API

Therapeutic Category Anti-Diabetic
CAS Number
461432-26-8
API Technology
Synthetic
Dose Form
Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Canada DMF, Korea DMF, Russia DMF, Indonesia, Switzerland

Mechanism of Action

Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion

Indication

FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Related APIs